Paul V. Plourde

home / authors / paul-v-plourde

Articles

16 Open-Label, Randomized, Multicenter, Phase 3, ELAINE 3 Study of the Efficacy and Safety of Lasofoxifene Plus Abemaciclib for Treating ER+/HER2–, Locally Advanced or Metastatic Breast Cancer With an ESR1 Mutation

16 Open-Label, Randomized, Multicenter, Phase 3, ELAINE 3 Study of the Efficacy and Safety of Lasofoxifene Plus Abemaciclib for Treating ER+/HER2–, Locally Advanced or Metastatic Breast Cancer With an ESR1 Mutation

Matthew P. Goetz, MD;Seth A. Wander;Thomas Bachelot;Gerald Batist;Javier Cortés, MD;Massimo Cristofanilli, MD;Giuseppe Curigliano;Alexandre de Nonneville;Einav Nili Gal-Yam;Komal Jhaveri;Cynthia X. Ma, MD, PhD;Heather A. Parsons, MD, MPH;Hope S. Rugo, MD;Sarah L. Sammons;Daniel G. Stover;Chris Twelves, MD, FRCP;Aditya Bardia, MD, MPH;Paul V. Plourde;David J. Portman;Senthil Damodaran
August 12th 2024
37 Open-Label, Phase 2, Multicenter Study of Lasofoxifene (LAS) Combined With Abemaciclib (Abema) for Treating Pre- and Postmenopausal Women With Locally Advanced or Metastatic ER+/HER2− Breast Cancer and an ESR1 Mutation After Progression on Prior Therapies

37 Open-Label, Phase 2, Multicenter Study of Lasofoxifene (LAS) Combined With Abemaciclib (Abema) for Treating Pre- and Postmenopausal Women With Locally Advanced or Metastatic ER+/HER2− Breast Cancer and an ESR1 Mutation After Progression on Prior Therapies

David J. Portman;Senthil Damodaran;Paul V. Plourde;Halle C. F. Moore, MD;Ian C. Anderson
April 27th 2023

Latest Updated Articles

NSABP B-42 trial results show that the assay was predictive of extended letrozole therapy response, identifying a patient subset with improved outcomes.
Published: August 9th 2024 | Updated: August 14th 2024
Gene Assay May Predict Extended Letrozole Benefits in Breast Cancer Subsets
OS Prolonged With Perioperative Chemo Vs Neoadjuvant CRT in Esophageal Cancer
Published: June 2nd 2024 | Updated: June 3rd 2024
OS Prolonged With Perioperative Chemo Vs Neoadjuvant CRT in Esophageal Cancer
Data from the CheckMate-67T trial support the biologics license application for subcutaneous nivolumab in multiple solid tumors.
Published: May 6th 2024 | Updated: May 21st 2024
FDA Accepts BLA for Subcutaneous Nivolumab in Solid Tumor Indications
A 71-Year-Old Male Presents for Evaluation of Painless Bump on His Chin
Published: May 27th 2011 | Updated: November 21st 2024
A 71-Year-Old Male Presents for Evaluation of Painless Bump on His Chin
Patient With Supraglottic Squamous Cell Carcinoma Develops Painful Swelling on Both Great Toes
Published: August 26th 2011 | Updated: November 21st 2024
Patient With Supraglottic Squamous Cell Carcinoma Develops Painful Swelling on Both Great Toes
How to Radiologically Assess and Follow Response After Treatment of Hepatocellular Carcinoma
Published: April 21st 2021 | Updated: November 21st 2024
How to Radiologically Assess and Follow Response After Treatment of Hepatocellular Carcinoma